ProMIS Neurosciences Inc. (PMN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $29.60M
Last updated: Nov 17, 2026 at 11:05 AM ET
ProMIS Neurosciences Inc. (PMN) Earnings: Report Dates and Results
ProMIS Neurosciences (PMN) is expected to report earnings on Mar 23, 2027. In the quarter ended Sep 30, 2026, ProMIS Neurosciences reported EPS of -$0.89, above the -$1.26 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PMN has an expected report date of Mar 23, 2027.
PMN Earnings Call
The latest PMN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 31 quarters below that had an estimate, PMN beat 12, missed 6 and matched 13. The widest gap in the table came in the quarter ended Sep 30, 2024, when EPS landed 548.76% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.89 | -$1.26 | N/A | +29.37% | Beat | N/A | 2 | 0 up, 0 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$1.28 | -$1.45 | N/A | +11.72% | Beat | N/A | 1 | 0 up, 0 down | Aug 13, 2026 | N/A |
| Mar 31, 2026 | -$1.26 | -$0.21 | N/A | -516.10% | Miss | N/A | 1 | 2 up, 0 down | May 12, 2026 | N/A |
| Dec 31, 2025 | -$30.05 | -$6.71 | -$7.57 - -$5.84 | -347.84% | Miss | -25141.7% | 3 | 2 up, 0 down | Mar 25, 2026 | N/A |
| Sep 30, 2025 | -$8.40 | -$9.99 | -$10.00 - -$9.98 | +15.92% | Beat | -177.3% | 2 | 1 up, 0 down | Nov 12, 2025 | N/A |
| Jun 30, 2025 | -$9.98 | -$6.04 | -$7.88 - -$4.20 | -65.23% | Miss | N/A | 4 | 1 up, 0 down | Aug 13, 2025 | N/A |
| Mar 31, 2025 | -$7.35 | -$4.30 | N/A | -70.93% | Miss | N/A | N/A | 0 up, 0 down | May 12, 2025 | N/A |
| Dec 31, 2024 | $0.12 | -$0.16 | N/A | +175.00% | Beat | N/A | N/A | 0 up, 0 down | Mar 31, 2025 | N/A |
| Sep 30, 2024 | $10.86 | -$2.42 | N/A | +548.76% | Beat | N/A | 1 | 0 up, 1 down | Nov 14, 2024 | N/A |
| Jun 30, 2024 | -$4.47 | -$4.85 | N/A | +7.84% | Beat | N/A | 1 | 0 up, 0 down | Aug 8, 2024 | N/A |
| Mar 31, 2024 | -$6.48 | -$6.87 | N/A | +5.68% | Beat | N/A | 1 | 0 up, 0 down | Apr 1, 2024 | N/A |
| Dec 31, 2023 | -$0.29 | -$0.27 | N/A | -7.41% | Miss | N/A | 1 | 0 up, 0 down | Mar 6, 2024 | N/A |
| Sep 30, 2023 | -$6.52 | -$11.42 | N/A | +42.91% | Beat | N/A | 1 | 0 up, 0 down | Nov 14, 2023 | N/A |
| Jun 30, 2023 | -$0.27 | -$0.27 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | Aug 14, 2023 | N/A |
| Mar 31, 2023 | -$0.58 | -$0.58 | N/A | +0.33% | Beat | N/A | N/A | N/A | May 15, 2023 | N/A |
| Dec 31, 2022 | -$1.17 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 8, 2023 | N/A |
| Sep 30, 2022 | -$1.11 | -$0.85 | N/A | -30.59% | Miss | N/A | N/A | N/A | Nov 14, 2022 | N/A |
| Jun 30, 2022 | -$0.48 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 12, 2022 | N/A |
| Mar 31, 2022 | -$0.60 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 13, 2022 | N/A |
| Dec 31, 2021 | -$0.32 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 17, 2022 | $4139 |
| Sep 30, 2021 | -$0.13 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 12, 2021 | N/A |
| Jun 30, 2021 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 12, 2021 | N/A |
| Mar 31, 2021 | -$1.22 | -$1.49 | N/A | +17.83% | Beat | N/A | N/A | N/A | May 14, 2021 | N/A |
| Dec 31, 2020 | -$0.11 | -$0.45 | N/A | +75.76% | Beat | N/A | N/A | N/A | Mar 31, 2021 | N/A |
| Sep 30, 2020 | -$0.60 | -$0.60 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 11, 2020 | N/A |
| Jun 30, 2020 | -$0.60 | -$0.60 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 13, 2020 | $1565 |
| Mar 31, 2020 | -$0.01 | -$0.43 | N/A | +97.67% | Beat | N/A | N/A | N/A | May 13, 2020 | N/A |
| Dec 31, 2019 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 18, 2020 | $1202 |
| Sep 30, 2019 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 14, 2019 | N/A |
| Jun 30, 2019 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 13, 2019 | N/A |
| Mar 31, 2019 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | May 14, 2019 | N/A |
| Dec 31, 2018 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 15, 2019 | $475 |
| Sep 30, 2018 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 13, 2018 | N/A |
| Jun 30, 2018 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 14, 2018 | N/A |
| Mar 31, 2018 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | May 11, 2018 | N/A |
| Dec 31, 2017 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | Mar 14, 2018 | $229 |
| Sep 30, 2017 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 13, 2017 | $9008 |
| Jun 30, 2017 | -$0.42 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 11, 2017 | N/A |
| Mar 31, 2017 | -$0.32 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 9, 2017 | $658 |
| Dec 31, 2016 | -$0.30 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 15, 2017 | $205 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$55.78, after $0.03 the year before. It was -$0.91 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$55.78 | -186033.3% |
| Dec 31, 2024 | $0.03 | N/A |
| Dec 31, 2023 | -$7.66 | N/A |
| Dec 31, 2022 | -$3.36 | N/A |
| Dec 31, 2021 | -$1.72 | N/A |
| Dec 31, 2020 | -$1.32 | N/A |
| Dec 31, 2019 | -$0.04 | N/A |
| Dec 31, 2018 | -$0.04 | N/A |
| Dec 31, 2017 | -$0.77 | N/A |
| Dec 31, 2016 | -$0.91 | N/A |
Earnings Calls
The only earnings call listed below, 2026Q3 for the period ended Sep 30, 2026, runs about 6,000 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,969 | 10 |
2026Q3 Earnings Call
Opening remarks
Carrie Pierce Vice President of Investor Relations and External Affairs Thank you, operator, and good afternoon, everyone. Earlier today, Promise issued a press release announcing our financial results for the third quarter ended September 30, 2026, and provided a corporate update. The press release is available on the Investor Relations section of our website, and our quarterly report on Form 10-Q has been filed with the SEC and on SEDAR+. Joining me on today's call are Neil K. Warma, our President and Chief Executive Officer, who will deliver our prepared remarks, and Dr. Larry Altstiel, our Chief Medical Officer, who will be available during the Q&A session. Before we begin, I would like to remind everyone that today's call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. These include, among others, statements regarding our clinical development plan and timelines for PMN310 and other product candidates; the interpretation and significance of the blinded interim data from our PRECISE-AD trial; our expectations regarding future clinical results and the timing of top-line data; our financial position and cash runway; and our overall business strategy. These statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the risk that early or interim results may not be indicative of final or top-line results. Please refer to the risk factors section in our most recent annual report on Form 10-K and our subsequent filings with the SEC, including our quarterly report on Form 10-Q for the quarter ended September 30, 2026. These statements speak as of today, November 12, 2026, and we undertake no obligation to update them except as required by law. With that, I will turn the call over to Neil.
Neil K. Warma President and Chief Executive Officer Thank you, Carrie. Good afternoon, everybody, and thank you for joining. Promise is entering probably the most important period in its history. Our Phase 1b study, PRECISE-AD, in Alzheimer's disease is nearing completion. All patient visits are expected to conclude this quarter, and unblinded 12-month top-line data remain on track for the first quarter of 2027. Today, I want to focus on four things: why recent events in the field sharpen rather than weaken the case for PMN310; the strength of the interim data from July that we have seen in our PRECISE-AD trial; how we will judge the top-line results coming shortly; and how we are positioned both strategically and financially to move efficiently once we have the data. First, I want to directly address the Phase 2 results reported two weeks ago by another company developing an antibody described as oligomer-selective. That trial did not meet its primary or secondary endpoints at 18 months.
Frequently Asked Questions About PMN
When is ProMIS Neurosciences's next earnings date?
ProMIS Neurosciences's next earnings report is expected for Mar 23, 2027.
Did PMN beat earnings estimates last quarter?
Yes. ProMIS Neurosciences reported EPS of -$0.89 for the quarter ended Sep 30, 2026, above the -$1.26 estimate, a 29.37% surprise.
What EPS do analysts expect from PMN next quarter?
The consensus EPS estimate for ProMIS Neurosciences for the quarter ending Dec 31, 2026 is -$1.12 from 7 analysts, with estimates from -$1.44 to -$0.90.
How often does PMN beat earnings estimates?
ProMIS Neurosciences beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -96.01%.
PMN pages: Overview, Earnings, Forecast, Competitors